Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.